FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Cytokine topics
Antibodies
Inflammation
Specificity
Immunotherapy
Major Histocompatibility Complex
Compatibility
Combination Therapy
Histocompatibility
Immune Response
Monoclonal Antibody
Stimulator
Therapeutics
Immunostimulator
Monoclonal
Proinflammatory

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Cytokine patents



      
           
This page is updated frequently with new Cytokine-related patent applications. Subscribe to the Cytokine RSS feed to automatically get the update: related Cytokine RSS feeds. RSS updates for this page: Cytokine RSS RSS


Date/App# patent app List of recent Cytokine-related patents
02/26/15
20150057175
 Method for monitoring hiv specific t cell responses patent thumbnailnew patent Method for monitoring hiv specific t cell responses
The invention relates to a method and a diagnostic kit for monitoring hiv specific t cell responses and identifying subjects capable of controlling hiv progression or preventing hiv infection altogether. The method is based on the combined use of boosted flow cytometry and toggle peptides and can cover a vastly larger set of effector functions than standard assays.
InstituciÓ Catalana De Recerca I Estudis AvanÇats
02/26/15
20150056680
 Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses patent thumbnailnew patent Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
The present invention concerns methods and compositions for stably tethered structures of defined compositions, which may have multiple functionalities and/or binding specificities. Particular embodiments concern homodimers comprising monomers that contain a dimerization and docking domain attached to a precursor.
Ibc Pharmaceuticals, Inc.
02/26/15
20150056222
 Anti-prlr antibodies and uses thereof patent thumbnailnew patent Anti-prlr antibodies and uses thereof
The present invention provides antibodies that bind to prolactin receptor (prlr) and methods of using the same. According to certain embodiments, the antibodies of the invention bind human prlr with high affinity.
Regeneron Pharmaceuticals, Inc.
02/26/15
20150056221
 Anti-prlr antibodies and uses thereof patent thumbnailnew patent Anti-prlr antibodies and uses thereof
The present invention provides antibodies that bind to prolactin receptor (prlr) and methods of using the same. According to certain embodiments, the antibodies of the invention bind human prlr with high affinity.
Regeneron Pharmaceuticals, Inc.
02/26/15
20150056215
 Methods of treating proliferative disorders with malate or derivatives thereof patent thumbnailnew patent Methods of treating proliferative disorders with malate or derivatives thereof
The present invention relates to methods, compositions, and diagnostic tests for treating and diagnosing proliferative disorders, such as cancel-, that result in dysregulation of malic enzyme 2. In particular, the methods and compositions include monotherapy with malate, or a derivative thereof, as well as combination therapy, such as malate, or a derivative thereof, combined with another therapeutic agent, such as a malic enzyme 2 inhibitor, an antineoplastic agent, a glycolysis inhibitor, an antiangiogenic agent, an immunomodulatory agent, an antibody, or a cytokine..
Beth Israel Deaconess Medical Center, Inc.
02/26/15
20150056160
 Chemically induced intracellular hyperthermia patent thumbnailnew patent Chemically induced intracellular hyperthermia
An invention relating to therapeutic pharmacological agents and methods to chemically induce intracellular hyperthermia and/or free radicals for the diagnosis and treatment of infections, malignancy and other medical conditions. The invention relates to a process and composition for the diagnosis or killing of cancer cells and inactivation of susceptible bacterial, parasitic, fungal, and viral pathogens by chemically generating heat, and/or free radicals and/or hyperthermia—inducible immunogenic determinants by using mitochondrial uncoupling agents, especially 2,4 dinitrophenol and, their conjugates, either alone or in combination with other drugs, hormones, cytokines and radiation..
St. Jude Pharmaceuticals, Inc.
02/19/15
20150051441
 Embryo implantation patent thumbnailEmbryo implantation
The present invention relates to methods of and compositions comprising cytokines for, improving the success rate of embryo implantation and the success rate of pregnancy rates in females, by providing an immunopermissive uterine environment prior to insemination or implantation of embryos. The methods of the present invention are used to make the uterus more receptive or less hostile to, for example, transferred embryos, sperm or other allografted tissue..
Ostara Biomedical Ltd
02/19/15
20150051156
 Method of treating leukemia using rice prolamin patent thumbnailMethod of treating leukemia using rice prolamin
The present invention relates to a method of treating leukemia using rice prolamin, comprising administering a daily dose of isolated prolamin to a patient suffering from leukemia for a period of time from 5 days to 10 days. For the treatment application, the rice prolamin can stimulate human peripheral blood mononuclear cell (pbmc) to produce cytokines, such as tumor necrosis factor-alpha, to inhibit growth of and induce differentiation of human leukemia cells.
Mackay Memorial Hospital
02/19/15
20150050715
 Stably tethered structures of defined compositions with multiple functions or binding specificities patent thumbnailStably tethered structures of defined compositions with multiple functions or binding specificities
The present invention concerns methods and compositions for stably tethered structures of defined compositions with multiple functionalities and/or binding specificities. Particular embodiments concern stably tethered structures comprising a homodimer of a first monomer, comprising a dimerization and docking domain attached to a first precursor, and a second monomer comprising an anchoring domain attached to a second precursor.
Ibc Pharmaceuticals, Inc.
02/19/15
20150050251
 Cosmetic preparations patent thumbnailCosmetic preparations
The invention is directed to methods for the treatment of wounds. Such methods utilize novel compositions, including but not limited to amnion-derived multipotent cells (herein referred to as amp cells), conditioned media derived therefrom (herein referred to as amnion-derived cellular cytokine suspension or accs), cell lysates derived therefrom, cell products derived therefrom, each alone or in combination..
Stemnion, Inc.
02/12/15
20150045422

Influenza treatment using targeted transient ribosomal inhibition


Novel methods are presented for treating influenza by using targeted transient ribosomal inhibition (ttri), with ttri drugs administered by inhalation, to silence expression of every protein underlying the etiology and pathology of the influenza infection, and without adversely effecting normal cells in the lungs. The therapeutic effect is dual antiviral and anti-inflammatory activity which is localized to the lungs.
02/12/15
20150044717

Devices and methods for observing eukaryotic cells without cell wall


The present invention relates to methods and devices for observing eukaryotic cells devoid of cell wall, in particular for observing the cytokinetic ring, the device comprising a plurality of wells suitable for containing only one single eukaryotic cell and characterized in that the dimensions of the wells constrain the cells into an oblong shape with a long axis parallel to the depth of the wells.. .
Inserm (institut National De La Sante Et De La Recherche Medicale)
02/12/15
20150044316

Method for preparing a purified extract of lonicera japonica thunberg and the composition comprising the same for preventing and treating sepsis and septic shock


The present invention relates to a method for preparing a purified extract of lonicera japonica thunberg and the composition comprising the same for preventing and treating sepsis and septic shock. The purified extract of purified extract of lonicera japonica thunberg potent antisepsis activity in severe sepsis clp model test, the effect on mods, and the inhibitory effect on various pro-inflammatory cytokines such as tnf-alpha, il-1beta, ifn-gamma, hmgb-1 etc, as well as it showed unexpectedly synergistic effect on the treatment of sepsis and septic shock in case of combining with the commercially available anti-septic agent such as broad-spectrum anti-biotic to the person skilled in the art, therefore, it can be useful in treating and preventing the sepsis and septic shock as a medicament and health functional food..
Huons Co., Ltd.
02/12/15
20150044258

Process for t cell expansion


An in vitro expansion process for rapid expansion of antigen specific t cells, such as allogeneic antigen specific t cells comprising the steps culturing in a gas permeable vessel a population of pbmcs (such as allogeneic pbmcs) in the presence of antigen, for example a peptide or peptide mix relevant to a target antigen(s), in the presence of an exogenous cytokine characterized in that the expansion to provide the desired population of t cells is 14 days or less, for example 9, 10, 11 or 12 days, such as 10 days. The disclosure also extends to t cell populations generated by and obtained from the method and the use of same in therapy..
Cell Medica Limited
02/12/15
20150044166

Compositions and methods for treatment of exercise-induced pulmonary hemorrhage or nasopharyngeal cicatrix


Methods, compositions, and medical device systems relating to treating exercise-induced pulmonary hemorrhage (eiph) and nasopharyngeal cicatrix (nc) in a mammal. For example, one method comprises administering through inhalation a composition comprising a physiologically acceptable carrier and an effective amount of each of one or more stem cell derived factors.
Riddle Institute
02/12/15
20150044134

Compositions, methods and kits for treatment of cancer and autoimmune diseases


The present invention is directed to fusion proteins having an il-21 cytokine portion and an anti-cd20 antibody portion, and methods of using such fusion proteins. The invention also provides pharmaceutical compositions and kits utilizing the il-21-anti-cd20 fusion proteins.
University Of Miami
02/05/15
20150038542

Uses of selective inhibitors of hdac8 and treatment of inflammatory conditions


Described herein are methods for treating a subject suffering from an inflammatory, autoimmune, or heteroimmune condition by administering to the subject a pharmaceutical composition containing a therapeutically effective amount of a compound that is a selective inhibitor of histone deacetylase 8. Also described herein are methods for decreasing secretion of pro-inflammatory cytokines by administering an hdac8-selective inhibitor compound.
Pharmacyclics, Inc.
02/05/15
20150037887

Method for producing nk cell-enriched blood preparation


It is intended to provide a method for producing an nk cell-enriched blood preparation, which is low invasive and is capable of conveniently and rapidly growing nk cells, etc. In blood collected from an organism.
Biotherapy Institute Of Japan
02/05/15
20150037283

Combination therapy with anti-cd74 antibodies provides enhanced toxicity to malignancies, autoimmune disease and other diseases


Disclosed are compositions and methods comprising combinations of anti-cd74 antibodies with a therapeutic agent that is attached to the anti-cd74 antibody or separately administered. Preferably, the therapeutic agent is an antibody that binds to an antigen different from cd74, such as cd19, cd20, cd21, cd22, cd23, cd37, cd40, cd40l, cd52, cd80, il-6, cxcr4 or hla-dr.
Ibc Pharmaceuticals, Inc.
01/29/15
20150031649

Co-administration of steroids and zoledronic acid to prevent and treat osteoarthritis


A combination therapy for treating osteoarthritis is disclosed. The combination therapy includes the co-administration of a steroid and zoledronic acid.
Voltarra Pharmaceuticals, Inc.
01/29/15
20150031625

Targeted vectors for cancer immunotherapy


This invention provides compositions and methods for treating cancer. More specifically this invention is directed to a targeted retroviral vector comprising a cytokine gene that can be administered either alone or in combination with a targeted retroviral vector comprising a cytocidal gene for treating cancer in a subject.
The University Of Southern California
01/29/15
20150030633

Application of mrna for use as a therapeutic against tumour diseases


The present invention relates to a pharmaceutical composition comprising at least one mrna comprising at least one coding region for at least one antigen from a tumour, in combination with an aqueous solvent and preferably a cytokine, e.g. Gm-csf, and a process for the preparation of the pharmaceutical composition.
Curevac Gmbh
01/29/15
20150030562

Methods of treating or preventing viral diseases by blocking interleukin-21


The invention provides a method of treating or preventing viral diseases in a mammal comprising administering to the mammal an interleukin (il)-21 blocking agent in an amount effective to treat or prevent the viral disease in the mammal. Also provided is a method of reducing the activation or recruitment of immune cells in a mammal comprising administering to the mammal an il-21 blocking agent in an amount effective to reduce the activation or recruitment of immune cells in the mammal.
The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services
01/22/15
20150025603

Methods and multi-vessel renal neuromodulation


Methods and apparatus are provided for multi-vessel neuromodulation, e.g., via a pulsed electric field. Such multi-vessel neuromodulation may effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers.
Medtronic Ardian Luxembourg S.a.r.l.
01/22/15
20150025223

System and producing interleukin receptor antagonist (ira)


The present invention relates to a system and method for producing high levels of autologous il-1ra cytokine, comprising: a blood collection vessel (1), a cover (4), a portion of separation gel (2), an anticoagulant portion (3), a plasma collection syringe comprising a sharp needle (9), a buffy coat collection syringe (11) and an incubation tube with cover (15). The vessel is adapted such that, when containing the whole blood (5), and centrifuged after treatment, yields separation fractions comprising, a first fraction of rbcs sediment (6), a second fraction of said gel (2), a third fraction comprising wbcs, platelets and), and fourth fraction of plasma solution (8)..
Estar Technologies Ltd
01/22/15
20150025009

Collagen and fibrin microthreads in a discrete thread model of in vitro acl scaffold regeneration


Compositions that include fibrin microthreads are provided. The compositions can include one or more therapeutic agents including cytokines and interleukins, extracellular matrix proteins and/or biologically active fragments thereof (e.g., rgd-containing peptides), hormones, vitamins, nucleic acids, chemotherapeutics, antibiotics, and cells.
Worcester Polytechnic Institute
01/22/15
20150024482

Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer


The present invention provides compositions and methods for generating a genetically modified t cells comprising a chimeric antigen receptor (car) having an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a cd3 zeta signaling domain, wherein the t cell exhibits prolonged exponential expansion in culture that is ligand independent and independent of the addition of exogenous cytokines or feeder cells.. .
The Trustees Of The University Of Pennsylvania
01/22/15
20150024459

Multivalent antibody complexes targeting igf-1r show potent toxicity against solid tumors


The present invention concerns methods and compositions comprising an anti-igf-1r antibody or fragment thereof for treatment of cancer or autoimmune disease. Preferably, the cancer is renal cell carcinoma, breast cancer or pancreatic cancer.
Ibc Pharmaceuticals, Inc.
01/22/15
20150023990

Alkoxy substituted imidazoquinolines


Imidazoquinoline compounds with an alkoxy substituent at the 6, 7, 8, or 9-position, pharmaceutical compositions containing the compounds, intermediates, methods of making, and methods of use of these compounds as immunomodulators, for inducing or inhibiting cytokine biosynthesis in animals and in the treatment of diseases including viral, and neoplastic, are disclosed.. .
3m Innovative Properties Company
01/22/15
20150023980

Combination pharmaceutical composition and methods of treating and preventing the infectious diseases


The present invention relates to a combination pharmaceutical composition comprising a) an activated-potentiated form of an antibody to at least one cytokine and b) an activated-potentiated form of an antibody to at least one receptor, and methods of treating and preventing the infectious diseases, including bacterial infections caused by different infectious agents such as pseudotuberculosis, whooping cough, yersiniosis, pneumonitis of different etiology, and acute and chronic viral infections such as acute respiratory tract infections, influenza of different types, acute viral hepatitis a, b, c and other types of hepatitis, the diseases and conditions caused by hiv or associated with hiv, including aids.. .
01/22/15
20150023972

Combination pharmaceutical composition and methods of treating and preventing the infectious diseases


The present invention relates to a combination pharmaceutical composition comprising a) an activated-potentiated form of an antibody to at least one cytokine and b) an activated-potentiated form of an antibody to at least one receptor, and methods of treating and preventing the infectious diseases, including bacterial infections caused by different infectious agents such as pseudotuberculosis, whooping cough, yersiniosis, pneumonitis of different etiology, and acute and chronic viral infections such as acute respiratory tract infections, influenza of different types, acute viral hepatitis a, b, c and other types of hepatitis, the diseases and conditions caused by hiv or associated with hiv, including aids.. .
01/22/15
20150023909

Lymph node-targeting nanoparticles


Provided are nanoparticles comprising heparin, chitosan, and at least one immunomodulatory agent, e.g. A cytokine.
Duke University
01/15/15
20150018821

Methods and intravascularly-induced neuromodulation


Methods and apparatus are provided for intravascularly-induced neuromodulation using a pulsed electric field, e.g., to effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, changes in cytokine upregulation, etc., in target neural fibers. In some embodiments, the intravascular pef system comprises a catheter having a pair of bipolar electrodes for delivering the pef, with a first electrode positioned on a first side of an impedance-altering element and a second electrode positioned on an opposing side of the impedance-altering element.
Medtronic Ardian Luxembourg S.a.r.l.
01/08/15
20150011419

Systems and methods for characterizing lupus erythematosus


The present invention provides systems and methods for characterizing biological markers in the urine of systemic lupus erythematosus (sle) subjects. In particular, the present invention relates to the detection of cytokines and chemokines in urine of sle subjects for determining nephritic disease states and kidney damage in sle subjects and the efficacy of agents and interventions used to treat lupus nephritis..
Renovar, Inc.
01/08/15
20150010946

Polynucleotides encoding zcytor17 ligand antibodies


The present invention relates to zcytor17lig polynucleotide, polypeptide and anti-zcytor17 antibody molecules. The zcytor17lig is a novel cytokine.
Zymogenetics, Inc.
01/08/15
20150010630

Functionalization of biomaterials to control regeneration and inflammation responses


The inventions provided herein generally relate to compositions and methods for controlling response of immune cells to at least one stimulus or condition (e.g., but not limited to, tissue damage, an implantable device and/or a cytokine) in vitro or in vivo. The compositions described herein comprise a biomaterial (e.g., a silk fibroin-based matrix) comprising at least one immune cell-modulating agent in an effective amount sufficient to selectively alter activation state of at least one type of immune cells (e.g., but not limited to macrophages and dendritic cells).
Trustees Of Tufts College
01/08/15
20150010553

Methods of treating inflammatory diseases using antibodies that bind both il-17a and il-17f


The present invention relates to blocking, inhibiting, reduceing, antagonizing or neutralizing the activity of il-17a and il-17f. Il-17a and il-17f are cytokines that are involved in inflammatory processes and human disease.
Zymogenetics, Inc.
01/08/15
20150010498

Immunocytokines for cancer treatment in combination with chemotherapeutic agents


This invention relates to the treatment of cancer using anti-cancer agents, such as doxorubicin or paclitaxel, in combination with antibody-interleukin 2 (il2) conjugates which target tenascin-c.. .
Philogen S.p.a.
01/08/15
20150010497

Combination of growth factors, cytokines, antibacterial/antiviral factors, stem cell stimulating factors, complement proteins c3a/c4a, and chemotactic factors


The present invention refers to a combination of growth factors, cytokines, antibacterial/antiviral factors, stem cell stimulating factors, complement proteins c3a/c4a, and chemotactic factors. The invention also relates to a process for the preparation of said combination from serum, placenta or colostrum and to composition containing said combination for use in the treatment of conditions requiring tissue repair and regeneration and for the substitution of stem cell therapies..
Bionest Ltd.
01/01/15
20150007357

Use of humanized mice to determine toxicity


The invention is directed to a method of determining whether an agent causes immune toxicity in a human comprising administering the agent to a non-human mammal that has been engrafted with human hematopoietic stem cells (hscs) and administered one or more human cytokines; and determining whether the agent causes immune toxicity in the non-human mammal. If the agent causes immune toxicity in the non-human mammal then the agent causes toxicity in a human.
Massachusetts Institute Of Technology
01/01/15
20150004184

Elastin digest compositions and methods utilizing same


The present invention provides compositions for the therapeutic and/or cosmetic treatment of elastin comprising tissues. Therapeutic and cosmetic compositions comprising an elastin digest stimulate the endogenous production of elastin and appear to enhance the elasticity of the skin and provide an external supply of peptide precursors of elastin that penetrate into the tissue to which it is applied.
Human Matrix Sciences, Llc
01/01/15
20150004180

Method for inducing a trif-bias


Compositions comprising a selected aminoalkyl glusoaminide 4-phosphate (agp) crx-547 to induce a trif-biased response in a human system, which results in reduced levels of myd88-dependent cytokines relative to the myd88-dependent cytokines induced by its diastereomer agp crx-527.. .
Glaxosmithkline Biologicals S.a.
01/01/15
20150004170

Angiogenic and immunologic applications of anti-cd160 specific compounds obtainable from mab cl1-r2


The present invention relates to biological and medical applications of an anti-cd160 monoclonal antibody (cl1-r2 cncm i-3204) and of the conservative equivalents thereof. It more particularly relates to the applications of these anti-cd160 compounds in the fields of ec angiogenesis, and nk and t cytokine production..
Inserm (institut National De La Sante Et De La Recherche Medicale)
12/25/14
20140378395

Peptides for the treatment of hearing


Peptides for the treatment of inflammation, and therapeutic uses and methods of using the same are disclosed. Peptides including a transducing sequence are effective for inhibiting cytokine activity and tnf-α secretion through interaction with toll-like receptor signaling pathways.
13therapeutics, Inc.
12/25/14
20140378371

Cytokine receptor peptides, compositions thereof and methods thereof


The invention provides a pharmaceutical composition including a peptide comprising at least a portion of a chemokine receptor or a g-protein coupled receptor and optionally a cytokine. The pharmaceutical composition of the invention may be used for altering immune system functioning, for example, to treat an immune system disorder, such as an autoimmune disease, multiple sclerosis, transplant rejection, psoriasis and asthma.
Symthera Canada Ltd.
12/25/14
20140378347

Diagnostic test


Disclosed are methods for conducting diagnostic tests for the detection of the inflammatory bowel diseases, such as crohn's disease and ulcerative colitis. Also described are methods for monitoring a patient by administering tests of the present invention.
Meso Scale Technologies, Llc
12/25/14
20140377234

Methods of expanding myeloid cell populations and uses thereof


The present disclosure relates to a method of expanding myeloid progenitor cells by culturing an initial population of cells in a medium comprising a mixture of cytokines and growth factors that promote growth and expansion of the myeloid progenitor cells. The expanded cell population provides a source of cells as therapeutic treatments for neutropenia and/or thrombocytopenia arising in patients subjected to myeloablative therapy and hematopoietic stem cell transplantation..
Cellerant Therapeutics, Inc.
12/25/14
20140377227

Tissue transplantation involving, and tissues modified by decellularization and recellularization of donor tissues for minimized or obviated rejection reactions


The method of tissue transplantation involving recellularizing of a donor organ with the utilization of the recipient's cytokines collected from the recipient's blood plasma at less than systemic pressure, and at the temperature greater than freezing and less than normal systemic temperature of the recipient's blood. Specifically, a method of harvesting a platelet-derived growth factors from platelet rich plasma (prp), the growth factors having increased weight..
12/25/14
20140377226

Tissue transplantation involving, and tissues modified by decellularization and recellularization of donor tissues for minimized or obviated rejection reactions


The method of tissue transplantation involving recellularizing of a donor organ with the utilization of the recipient's cytokines collected from the recipient's blood plasma at less than systemic pressure, and at the temperature greater than freezing and less than normal systemic temperature of the recipient's blood. Specifically, a method of harvesting a platelet-derived growth factors from platelet rich plasma (prp), the growth factors having increased weight..


Popular terms: [SEARCH]

Cytokine topics: Antibodies, Inflammation, Specificity, Immunotherapy, Major Histocompatibility Complex, Compatibility, Combination Therapy, Histocompatibility, Immune Response, Monoclonal Antibody, Stimulator, Therapeutics, Immunostimulator, Monoclonal, Proinflammatory

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Cytokine for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Cytokine with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         









0.6849

3233

0 - 1 - 73